Development of an inhibitor in a child with severe hemophilia B treatment with immunosuppression and an extended desensitization protocolRoberts, Jonathan C.a,b; Jesudas, Rohitha; Tarantino, Michael D.a,bBlood Coagulation & Fibrinolysis: September 2019 - Volume 30 - Issue 6 - p 291–294 doi: 10.1097/MBC.0000000000000829 CASE REPORTS Buy Abstract Author InformationAuthors Article MetricsMetrics Development of neutralizing alloantibodies in hemophilia B is a less common, but clinically challenging phenomenon. Novel therapeutics for hemophilia B have recently been developed and reports of clinical experience with these agents outside of clinical trials are needed. We report development of an inhibitor in a child with severe hemophilia B, and subsequent immune tolerance induction using an extended desensitization protocol with the addition of immunosuppression. This case highlights successful management of a rare complication in a rare bleeding disorder and the need for additional investigation into this infrequent and clinically challenging occurrence. aBleeding & Clotting Disorders Institute bDepartment of Pediatrics, University of Illinois College of Medicine at Peoria, Peoria, IL Correspondence to Jonathan C. Roberts, MD, Bleeding & Clotting Disorders Institute, 9128 N Lindbergh Dr, Peoria, IL 61615, USA Tel: +1 309 692 5337; fax: +1 309 693 3913; e-mail: firstname.lastname@example.org Received 4 February, 2019 Revised 17 April, 2019 Accepted 4 June, 2019 Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.